- 10 federal government, policy updates for dentists to know
- The highest-paid ophthalmologist in the 10 largest Northeastern cities
- Arizona cardiology group pays $4.75M to settle false claims allegations
- Why AI is keeping dental practice owners up at night
- OSF HealthCare uses text outreach after ED visits — and sees 33% engagement
- Drug affordability worries highest since 2018: KFF poll
- Eliquis may be safer than Xarelto for patients with deep blood clots: Study
- Medicare spending on ASCs jumps 16% in 1 year: MedPAC
- 47 recent hospital, health system executive moves
- Lawmakers scrutinize payers: What it means for healthcare providers
- The uneven competition in physician markets
- ‘Dark Money’ Group Angles for Higher Medicare Advantage Payments
- Judge grants Mississippi hospital pause on Medicaid debt repayment
- Inside the erosion of independence in cardiology
- OIG green-lights ASC cataract supply discount proposal
- Arkansas regional hospital taps chief medical officer
- Tampa General hospital 2nd in the world to get women’s surgery designation
- Nurses plan strike at Northern Light Eastern Maine
- Children’s Hospital of Philadelphia anesthesiologist receives lifetime achievement award
- MUSC Health names hospital CEO
- Oceans Behavioral Hospital debuts virtual outpatient program
- With $50B rural health fund, 23rd state joins PA licensure compact
- UF Health opens 24K-square-foot orthopedic surgical center
- Illinois health association to open $4M dental practice
- Medtronic inks ASC deal with Access GPO
- 30+ dental industry updates in California, Florida and Texas
- North Carolina weighs bill to cut facility fees for hospital-owned clinics
- Heartland Dental expands in 4 states
- Crestwood Behavioral Health names program chief
- Dartmouth hospital launches social work department
- 5 DSOs making headlines
- Oceans behavioral health hospital taps CEO
- Pediatric dental, orthodontic practice building sold for $4.4M
- San Francisco secures $100M to expand behavioral health treatment to 3 sites
- Study Finds 'Forever Chemicals' on California Fruits and Vegetables
- Bad News for Multitaskers: Your Brain Can’t Really Do It
- OSF HealthCare uses digital therapeutics to create a digital path to care
- Former Tenet CFO joins Acadia Healthcare board
- About 3,000 Wayfair Dressers Recalled Over Child Tip-Over Risk
- Microsoft Unveils AI Health Tool That Can Read Your Medical Records
- FDA Town Hall: FDA’s Quality Management System Regulation (QMSR) – Medical Device Risk-Based Inspections
- FDA Town Hall: FDA’s Quality Management System Regulation (QMSR) – Medical Device Risk-Based Inspections
- The feds will overpay Medicare Advantage plans by $76B this year, MedPAC estimates
- FDA Launches New Adverse Event Look-Up Tool
- FDA Launches New Adverse Event Look-Up Tool
- FDA Issues Final Guidance on Medical Devices with Indications Associated with Weight Loss
- FDA Issues Final Guidance on Medical Devices with Indications Associated with Weight Loss
- The 510(k) Pathway in 2026: Navigating a Shifting Regulatory and Political Landscape for Medical Devices
- The 510(k) Pathway in 2026: Navigating a Shifting Regulatory and Political Landscape for Medical Devices
- Bayer found to have discredited pharma industry after Roche row
- Industry Voices—Fast answers, fragile data: the trust problem in AI-driven healthcare analytics
- Pfizer CEO Albert Bourla collects $27.6M in 2025 pay following Metsera, MFN deals
- GSK catches up to Pfizer, Moderna with FDA expansion for Arexvy
- Experts Weigh in on Digital Health Wearables for Neurological Health
- Ultra-Processed Foods Bad For Bone Health, Researchers Say
- AI-Generated Meal Plans For Dieting Teens Could Be Harmful, Study Warns
- Fertility Treatments Aren't Linked To Added Cancer Risk For Women, Study Concludes
- There's One Simple Way Cancer Patients Can Ward Off 'Chemo Brain,' Study Finds
- Younger Stroke Survivors Face Unique Mental Health Hurdles
- 'Manufacturing is access': How Gilead's early production moves set PrEP med Yeztugo up for success
- Families Scramble To Pay Five-Figure Bills as Clock Ticks on Promised Preauthorization Reforms
- Doctors Warn of a Deadly Complication From Measles Outbreaks
- Medicare Advantage ‘Dark Money’ Group Attempts To Win Higher Payments for Insurance Companies
- FDA scolds CDMO Simtra with warning letter over contamination fumbles
- FDA fires off another manufacturing-related CRL, this one to Hyloris
- Florida woman accused of operating illegal dental clinic out of home
- North Carolina updates mental health bed registry
- Healthcare worker burnout, anxiety widespread, GAO finds
- Utah passes bill expanding hygienists’ ability to practice without dentist supervision
- Virginia weighs spending cap on Medicaid dental services to resolve budget shortfall: 5 notes
- What the Health? From KFF Health News: RFK Jr.’s Very Bad Week
- Report on doctor's sexual abuse spurs promises of structural change at Columbia. Survivors say it isn't enough
- Fierce Pharma Asia—A trio of Lilly investments; Pfizer, Sciwind's GLP-1 nod; Astellas' MFN windfall
- Remarks at the Investor Advisory Committee Meeting
- Pediatric Allergy Specialist: Feed Babies Allergenic Foods Earlier, Not Later
- FDA Warns Novo Nordisk Broke Safety Reporting Rules
- Doctors Warn Patients to Research Cosmetic Surgery Providers Before Getting Work Done
- Adam’s Lib: Remarks at the Meeting of the SEC Investor Advisory Committee
- Remarks for the Investor Advisory Committee Meeting
- Gallup poll: One in three Americans cutting back on daily expenses to pay for healthcare
- AMA: Physicians' use of AI doubled from 2023 to 2026
- Study Suggests Epilepsy Drug Sulthiame May Help Treat Sleep Apnea
- At HIMSS26, Dr. Oz, CMS officials push agentic AI adoption. Are Medicare beneficiaries ready?
- Stryker Cyber Attack Being Reported as Iranian War Retaliation
- Stryker Cyber Attack Being Reported as Iranian War Retaliation
- After China outlay, Lilly plugs $126M into Japan manufacturing plant expansion
- Legend remains bullish on Carvykti growth despite threat from J&J’s Tecvayli
- FDA rolls out new streamlined adverse event monitoring system, eyes $120M in savings
- Eisai chooses 'Pokémon Sleep' app to battle bad sleep habits in awareness campaign
- Electrodes Partially Restore Movement, Sensation In Spinal Cord Patients
- Genetic Test May Predict Leukemia Relapse Risk
- Switching GLP-1 Medications Is Common, Can Help People Stick With Weight-Loss Treatment
- Millions Of Americans Making Financial Sacrifices To Afford Health Care, Survey Finds
- More Concussions Linked To Worse Brain Health Among Recent College Grads
- Years of Specialized Support Essential with Rare Heart Defects
- In latest compounding clash, Lilly flags high levels of 'impurity' in tirzepatide knockoffs with vitamin B12
- New Medicaid-focused doula provider Malama launches with $9.2M
- As Lung Disease Threatens Workers, Lawmakers Seek Protections for Countertop Manufacturers
- Republicans Fret Over RFK Jr.’s Anti-Vaccine Policies While MAHA Moms Stew
- Rare disease drug sales to surge past $400B by 2032 despite FDA volatility: Evaluate report
- Microsoft unveils Copilot Health as an AI health companion for consumers
- HIMSS26: HHS officials offer updates on interoperability efforts, information blocking enforcement
- Despite insurers' expense pains, Tenet Healthcare is securing healthy commercial rates through 2027
- Study Links State Taxes to COVID Lockdown Decisions
- Aetna to pay $117.7M to settle Medicare Advantage upcoding allegations: DOJ
- UPDATED: Stryker hit by international cyberattack linked to pro-Iran group
- AHA: Hospitals' total expenses rose by 7.5% in 2025
- AstraZeneca recruits Joshua Jackson, Philadelphia Flyers' Gritty to cancer screening push
- As Lilly flourishes in Q4, peer projections signal looming sector slowdown in 2026
- FDA May Allow Some Flavored Vapes Aimed at Adults
- Dark Sweet Cherries May Help Slow Aggressive Breast Cancer, Mouse Study Suggests
- FDA Approves Leucovorin for Rare Brain Disorder, Not Autism
- Joint Economic Committee report: Medicare Advantage overpayments drive up Part B premiums
- Veeva shells out $100M for Ostro and its AI chat tool for pharma brand engagement
- Lilly beefs up oral GLP-1 capacity with $3B manufacturing pledge in China
- UCB's Bimzelx continues winning streak with victory over AbbVie's Skyrizi
- Lowering Parents' Stress Can Reduce Risk Of Childhood Obesity
- Multilingualism Might Not Aid Brain Aging, Researcher Argues
- 15-Year Study Shows Sharp Rise in Depression Among U.S. College Students
- Repealing Motorcycle Helmet Laws Leads to More Severe Crashes, Millions in Added Treatment Costs
- Why Childhood Cavities May Predict Adult Heart Disease
- Physical Therapy Costs Vary Widely In U.S., Study Finds
- J&J's Joaquin Duato joins $30M CEO pay club with 30% compensation boost for 2025
- Primary Care Is in Trouble. So Doctors Band Together To Boost Their Market Power.
- Cosmetic Surgery Investigation Prompts Warnings for Patients, and a Push for Tighter Safety Standards
- Skyhawk taps Teva alum to steer commercial path, while Santhera names new CCO to grow DMD sales
- Driving the news at HIMSS26: Verily, Samsung ink collaboration; Meditech's latest AI solutions
- Remarks at the Institute of International Bankers 2026 Annual Washington Conference
- Fostering Regulatory Harmony Between the SEC and CFTC
- Here's where hospital markets are the most concentrated
- A look at how CVS is leaning on 'agentic twins' in developing consumer tech
- Patent expirations push biopharma industry toward a tougher 2026
- Bancos, primera línea de batalla contra los fraudes financieros a adultos mayores
- Sandoz to set up standalone biosimilars unit as it eyes upcoming 'golden decade' of patent losses
- AbbVie's Robert Michael earns hefty pay bump to $32.5M in 2nd year as CEO
- NYU Stern report calls for private equity reforms to safeguard quality of care
- Remarks at the International Bar Association’s 24th Annual International Conference on Private Investment Funds
- Raw Oysters and Clams Recalled After Norovirus-Like Illness Outbreak in Washington
- Mammograms May Also Reveal Hidden Heart Disease Risk, Study Finds
- Chile Becomes First Country in the Americas To Eliminate Leprosy
- Going Abroad? CDC Warns Travelers About Polio Risk in Several Countries
- The Fierce Healthcare team on the Fierce 15 of 2026
- Centene's stock falls as CEO London outlines ongoing ACA headwinds
- AI-fueled misdiagnoses, rural care barriers are 2026's top patient safety threats: ECRI
- Patients want price transparency, e-commerce experience from pharma DTP platforms: survey
- Carrum Health teams up with Virta Health on a comprehensive weight loss solution
- Nearly Half of U.S. Kids Lack Adequate Sleep, Survey Shows
- Trump Caused Immediate Decrease in Acetaminophen Rx's For Pregnant Women, Study Finds
- Students Spend A Third Of Their School Day On Their Smartphone, Study Says
- Daily Multivitamins Slow Aging, Clinical Trial Finds
Not exactly over-the-counter, actually pharmacist prescribed birth control pills:
Over-the-counter birth control hitting shelves, thanks to Michigan firm
- The FDA decided last year that a longtime birth control pill was safe enough to gain over-the-counter status.
- The drug, Opill, is the product of a Grand Rapids-based company which has headquarters in Ireland, too.
- The pill began shipping Monday at a cost of $20 a month, or $50 for a three-month supply.
By Robin Erb - March 4, 2024
The first over-the-counter daily birth control pill began shipping to pharmacies Monday, dramatically boosting convenience and access among oral contraceptives, especially for low-income women, those living in rural areas and those without easy access to transportation or child care.
On Monday, Opill — which is offered in a 28-day blister pack and is 98% effective against unplanned pregnancies when taken as directed — became available for the first time nationally.
It is the product of drugmaker Perrigo, which is based both in Grand Rapids and Ireland.The drug is being manufactured in Ireland, and its active ingredient, norgestrel, is being manufactured in Germany.
After months of anticipation by medical groups and consumer groups, the company announced the first, long-awaited shipments Monday morning.
“It’s revolutionary in terms of having women take control of their reproductive choices,” said Dr. Ann Gillett-Elrington, a staff physician and board-certified obstetrician at Western Wayne Family Health Centers.
The suggested retail price will be $20 for a one-month supply, $50 for a three-month supply and $90 for a six-month supply.
The relatively low cost is good news, especially for the uninsured or without regular medical care, she said.
“Appointments — sometimes they're far in between. People can get pregnant in the interval,” she said. “They also have to take time off from work (for an appointment) and they might have to make child arrangements.”
Given the cost of those things or an unplanned pregnancy, the pill “is very cost-effective,” she said.
The pill will be available at major retail pharmacies, including Walgreens and CVS, and through Amazon, said Perrigo’s chief commercial officer, Sara Young, who called the pill “groundbreaking.”
The French drugmaker HRA Pharma had begun seeking FDA approval for its over-the-counter product when Perrigo purchased the company in a sale completed in 2022.
Opill will also be sold online directly to consumers from opill.com on March 18, she said.
Long awaited
The U.S. Food and Drug Administration switched Opill, a progestin-only tablet, to an over-the-counter drug in July. Because it doesn’t contain the hormone estrogen, it may have few side effects. Most common side effects are irregular bleeding, headaches, dizziness, nausea, increased appetite, abdominal pain, cramps or bloating, according to the FDA’s July announcement.
The drug had originally been approved in 1973. In making its decision last year, the FDA made it clear that the pill was safe and effective enough that Americans could decide on their own — with consulting with a doctor — whether Opill is appropriate for them.
That’s “obviously a very important step forward regarding convenience and access,” said Dr. Mark Fendrick, an internal medicine doctor and director of the Center for Value-Based Insurance Design at the University of Michigan.
About 26 million Americans are uninsured, according to the U.S. Census, making it difficult or too expensive to get regular medical care, he said.
Family planning, including options for oral contraception, is “a very effective, equitable and important public health and population health measure,” he said, so Opill is a “great step forward for access.”
Moreover, limitations or bans on abortion in some states make pregnancy prevention even more critical.
For its part, Right to Life of Michigan, aligning with national leaders of Right to Life, takes no position on products that prevent an egg’s fertilization, legislative director Genevieve Marnon, told Bridge Michigan, Monday.
Still unknown is whether insurers, including the state’s Medicaid program, will cover the costs of the pill.
The pill likely will show up at local pharmacies later this month, said Farah Jalloul, state emergency preparedness coordinator at the Michigan Pharmacists Association. And pharmacies can decide whether they will carry the pill, she noted, though she added that most undoubtedly will do so.
When it hits the shelves, it will be available to consumers of any age — a concern for some who worry about adolescents or some adults who might be unable to follow directions or understand contraindications.
Among those who should not take Opill are women with a history of breast cancer. People who have any other form of cancer should consult their doctor before taking Opill. And Opill is not for use as emergency contraception nor does it prevent sexually transmitted infections.
Ideally, said Gillett-Elrington at Western Wayne Family Health Centers, a young person or an adult with questions will talk with a trusted medical professional before taking Opill, though there are no guarantees, she acknowledged.
The drug works mainly by thickening a person’s cervical mucus, thereby blocking sperm from reaching the egg. Opill also may prevent an egg from implanting or altogether block its release from the ovaries. But a pill from the 28-day blister pack must be taken every day.
More than one in three women using oral contraceptives (36%) had missed taking doses because they were unable to get their next supply, according to a 2022 KFF Women’s Health Survey.Medical groups, including the American Medical Association, had urged the FDA to approve over-the-counter daily contraception. And the American College of Obstetricians and Gynecologists Monday lauded the release, and released guidelines for clinicians.
ACOG President Dr. Verda J. Hicks, called Opill a safe drug for patients of all ages, including adolescents.
It’s a “key component of reproductive health care” in a country where there are “increasing healthcare deserts … where people do not have access to gynecologic care,” she said in a prepared statement.
Despite some initial concerns that consumers might not be able to understand how to take the pills or why some patients should not take the pills, ACOG doctors “trust our patients to determine if this OTC method is best for them.”
Perrigo executed a corporate tax inversion to Ireland eleven years ago to avoid U.S. corporate taxes. It was 'acquired' by Irish-based Elan Corporation for $ 8.6 billion. The combined company is now known as Perrigo Company plc.
Get MHF Insights
News and tips for your healthcare freedom.
We never spam you. One-step unsubscribe.














